Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibrutinib + rituximab + dexamethasone + cytarabine + cisplatin + oxaliplatin
- Development stage
- Discontinued
- Lead developer
- The Lymphoma Academic Research Organisation
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen consists of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib and immunochemotherapy backbones R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) or R-DHAOx (rituximab, dexamethasone, cytarabine, and oxaliplatin). Developed and investigated by The Lymphoma Academic Research Organisation (LYSARC), this regimen was evaluated in a Phase Ib study for patients with various B-cell lymphomas, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Ibrutinib works by covalently and irreversibly inhibiting BTK, a key component of the B-cell receptor signaling pathway. Rituximab is a monoclonal antibody targeting CD20, while the chemotherapy components provide cytotoxic effects through DNA synthesis inhibition (cytarabine), DNA cross-linking (cisplatin/oxaliplatin), and anti-inflammatory/lympholytic activity (dexamethasone). Clinical results indicated significant hematological and infectious toxicities, leading to the inability to recommend a dose for Phase II development with the R-DHAP backbone.
- Brand names
- ImbruvicaRituxanMabThera
- Other names
- ibrutinib + R-DHAPibrutinib + R-DHAOxibrutinib + immunochemotherapies
02
Targets
DNA polymerase familyCD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on ibrutinib + rituximab + dexamethasone + cytarabine + cisplatin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibrutinib + rituximab + dexamethasone + cytarabine + cisplatin + oxaliplatin.